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Abstract: Teixobactin is a recently described antimicrobial peptide that shows high activity against
gram-positive bacteria as well as mycobacterium tuberculosis. Due to both its structure as a head-to-side
chain cyclodepsipeptide and its activity, it has attracted the attention of several research groups.
In this regard, a large number of analogs with substitutions in both the cycle and the tail has been
described. Here, we report the contribution of the N-terminus residue, N-Me-D-Phe, to the activity of
Arg10-teixobactin. On the basis of our findings, we conclude that the N-terminus accepts minimum
changes but not the presence of long alkyl chains. The presence of a positive charge is a requirement
for the activity of the peptide. Furthermore, acylation of the N-terminus leads to total loss of activity.
Keywords: antimicrobial peptides; teixobactin; lipophilicity; solid-phase peptide synthesis;
cyclic depsipeptides
1. Introduction
The isolation of a new anti-microbial peptide (AMP) called teixobactin in 2015 by Ling et al.
raised great expectations because it is one of the few new antibiotics to have been reported in recent
years [1,2]. This antibiotic shows high activity against gram-positive bacteria as well as Mycobacterium
tuberculosis. Teixobactin (Figure 1) is a head-to-side chain cyclodepsipeptide that contains hydrophilic
and hydrophobic residues [3,4]. Thus, the tail of the natural peptide contains four polar amino
acids, L-allo-enduracididine, two Ser, and D-Gln, and four non-polar Ile residues, one Ala and one
N-Me-D-Phe residue at the N-terminus. Finally, a D-Thr is the branching unit to form the cyclic moiety.
Molecules 2017, 22, 1632; doi:10.3390/molecules22101632 www.mdpi.com/journal/molecules
Molecules 2017, 22, 1632 2 of 9
Molecules 2017, 22, 1632 2 of 8 
 
 
Figure 1. Chemical structure of teixobactin. 
Taking Arg10-teixobactin (1) as a reference, in which the unusual L-allo-Enduracididne is replaced by 
L-Arg [2,5], Nowick’s and our group have independently confirmed the importance of maintaining a 
balance between the hydrophobic and hydrophilic residues for keeping the activity [3,4]. The main 
conclusions drawn from those studies are that the replacement of polar or neutral amino acids by Lys 
retains or improves the activity of the molecule, while replacing the non-polar amino acids by Lys 
leads to total loss of activity. Only the replacement of non-polar Ile by cyclohexylglycine (Chg) has 
been reported to retain activity [4]. In a further step towards understanding the contribution of the 
cationic residues to the activity of teixobactin, our group has prepared a library of more than  
25 teixobactin analogs in which extra basic residues (Lys, Orn, Dap) were introduced into positions 
occupied by polar/neutral amino acids, without affecting the N-terminus residue [6]. That study 
concluded that the activity of a cationic teixobactin analog requires a maximum of three or four 
positive charges. Thus, the introduction of an extra charge leads to total loss of activity [6]. 
However, little attention has been paid to the role of the N-terminus residue for teixobactin,  
N-Me-D-Phe. We and Madder-Taylor-Singh’s group have demonstrated the importance of the D-
configuration, and reported that the Me group cannot be switched for an acetyl (N-Ac-D-Phe-Arg10-
teixobactin (9)) [5,7]. Furthermore, in a totally different approach, Nowick et al. prepared a short 
version of teixobactin, namely lipobactin, which retains most of its activity and in which the last five 
residues (two Ile (L, and D-allo), Ser, D-Gln, and N-Me-D-Phe) are replaced by a dodecanoyl moiety [4,8]. 
With the aim to further explore the contribution of the N-Me-D-Phe to the activity of teixobactin, 
here we synthesized a small library of Arg10-teixobactin analogs. As we previously demonstrated that 
the replacement of N-Me-D-Phe by N-Me-D-Lys leads to total loss of activity [6], here we concentrated 
on increasing the hydrophobicity of the N-terminus by introducing extra tails to this terminus. 
Lipophilicity plays a crucial role in the activity of all peptides, as well as in their transport and 
distribution within biological systems [9–11]. However, for AMPs, increasing hydrophobicity can be 
a way to promote binding to bacterial membranes, thereby causing greater disruption. For instance, 
some species such as S. aurus show a limited electrostatic surface potential with the hydrophilic 
AMPs, causing the AMPs to bind to the bacterial membrane in a different way [12]. Furthermore, the 
membrane binding of such peptides is salt sensitive, leading to limited potency at physiological ionic 
strength; however, increasing their hydrophobicity means reducing their salt sensitivity, as well as 
increasing their bactericidal potency. As an example, increasing the hydrophobicity of the AMP 
CNY21 (CNYITELeRRQHARASHLGLAR) improved peptide adsorption, led to peptide liposome 
leakage, and enhanced activity against Escherichia coli and Pseudomonas aeruginosa [12]. Furthermore, 
it has been demonstrated that the replacement of the aliphatic acyl moiety of polymyxin B or colistin by 
aromatic or fatty acid substituents has a great impact on the antimicrobial activity of the analogs [13–17]. 
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Taking Arg10-teixobactin (1) as a reference, in which the unusual L-allo-Enduracididne is replaced
by L-Arg [2,5], Nowick’s and our group have independently confirmed the importance of maintaining
a balance between the hydrophobic and hydrophilic residues for keeping the activity [3,4]. The main
conclusions drawn from those studies are that the replacement of polar or neutral amino acids by Lys
retains or improves the activity of the molecule, while replacing the non-polar amino acids by Lys leads
to total loss of activity. Only the replacement of non-polar Ile by cyclohexylglycine (Chg) has been
reported to retain activity [4]. In a further step towards understanding the contribution of the cationic
residues to the activity of teixobactin, our group has prepared a library of more than 25 teixobactin
analogs in which extra basic residues (Lys, Orn, Dap) were introduced into positions occupied by
polar/neutral amino acids, without affecting the N-terminus residue [6]. That study concluded that
the activity of a cationic teixobactin analog requires a maximum of three or four positive charges.
Thus, the introduction of an extra charge leads to total loss of activity [6].
However, little attention has been paid to the role of the N-terminus residue for teixobactin,
N-Me-D-Phe. We and Madder-Taylor-Singh’s group have demonstrated the importance of the D-
configuration, and reported that the Me group cannot be switched for an acetyl (N-Ac-D-Phe-Arg10-
teixobactin (9)) [5,7]. Furthermore, in a totally different approach, Nowick et al. prepared a short
version of teixobactin, namely lipobactin, which retains most of its activity and in which the last
five residues (two Ile (L, and D-allo), Ser, D-Gln, and N-Me-D-Phe) are replaced by a dodecanoyl
moiety [4,8].
With the aim to further explore the contribution of the N-Me-D-Phe to the activity of teixobactin,
here we synthesized a small library of Arg10-teixobactin analogs. As we previously demonstrated that
the replacement of N-Me-D-Phe by N-Me-D-Lys leads to total loss of activity [6], here we concentrated
on increasing the hydrophobicity of the N-terminus by introducing extra tails to this terminus.
Lipophilicity plays a crucial role in the activity of all peptides, as well as in their transport and
distribution within biological systems [9–11]. However, for AMPs, increasing hydrophobicity can be
a way to promote binding to bacterial membranes, thereby causing greater disruption. For instance,
some species such as S. aurus show a limited electrostatic surface potential with the hydrophilic
AMPs, causing the AMPs to bind to the bacterial membrane in a different way [12]. Furthermore,
the membrane binding of such peptides is salt sensitive, leading to limited potency at physiological
ionic strength; however, increasing their hydrophobicity means reducing their salt sensitivity, as well as
increasing their bactericidal potency. As an example, increasing the hydrophobicity of the AMP CNY21
(CNYITELeRRQHARASHLGLAR) improved peptide adsorption, led to peptide liposome leakage,
and enhanced activity against Escherichia coli and Pseudomonas aeruginosa [12]. Furthermore, it has been
demonstrated that the replacement of the aliphatic acyl moiety of polymyxin B or colistin by aromatic
or fatty acid substituents has a great impact on the antimicrobial activity of the analogs [13–17].
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2. Results and Discussion
2.1. Synthetic Strategy
The N-terminus Arg10-teixobactin analogs (Figure 2, 2–6, 8–10) were synthesized using strategies
developed by our group for the previous analogs [2,3,7].
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Briefly, chloro-tritylchloride (CTC) polystyrene resin was used for the elongation of the peptide 
chain using Fmoc-amino acids, with Ala as C-terminus, using 1-[bis-(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]-pyridinium 3-oxide hexafluorophosphate (HATU)/Diisopropylethylamine 
(DIEA) as coupling method and dimethylformamide (DMF) as solvent. After the incorporation of 
Fmoc-Ile6, acylation of the β-hydroxyl group of D-Thr was carried out with Alloc-Ile-OH/DIC-DMAP 
in DMF-dicholoromethane (DCM) (8:2), followed by the removal of the Alloc group, and further 
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Figure 2. Chemical structure of the teixobactin analogs 2–6, 8–10 used in this study; “2–6, 8–10” are the
protected linear precursors of 2–6, 8–10.
Briefly, chloro-tritylchloride (CTC) polystyrene resin was used for the elongation of the peptide
chain using Fmoc-amino acids, with Ala as C-terminus, using 1-[bis-(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]-pyridinium 3-oxide hexafluorophosphate (HATU)/Diisopropylethylamine (DIEA)
as coupling method and dimethylformamide (DMF) as solvent. After the incorporation of Fmoc-Ile6,
acylation of the β-hydroxyl group of D-Thr was carried out with Alloc-Ile-OH/DIC-DMAP in
DMF-dicholoromethane (DCM) (8:2), followed by the removal of the Alloc group, and further acylation
with Alloc-Arg (Pbf)-OH. The introduction of the rest of the amino acids was then continued using
Fmoc chemistry. The last amino acid, D-Phe, was incorporated as an Fmoc derivative. In our previous
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synthesis, the last residue was Boc-N-Me-D-Phe, with the aim to protect the N-terminus during
cyclization [2,3,6,7].
Analog 2, which has a free amine at N-terminus, was synthesized by removing the Fmoc of D-Phe
and then reprotecting the amino function as Boc by means of Boc2O/DIEA (1:2) in DMF, to prevent its
reaction during the cyclization step.
The remaining modifications at the N-terminus were performed in solid-phase through alkylation,
acylation, or guanidination, after the removal of the last Fmoc group. The first group (3–6) was achieved
by the reductive amination of the D-Phe analog by reaction with the corresponding aldehydes in the
presence of NaBH3CN and HOAc in dry tetrahydrofuran (THF). The reaction with formaldehyde-led,
as expected, to a complete double methylation (3). The reaction with decanal was carried out with
excess aldehyde to trigger the formation of an approximately equimolar mixture of the mono- (5) and
the di- (6) decanyl derivatives. These compounds were separated after the cyclization step, which was
carried out in solution, and subjected to deprotection. Finally, the reaction with benzaldehyde rendered
only the mono derivative (4). Acylation with decanoic acid of the D-Phe analog took place smoothly
with DIC and K-Oxyma, rendering the decanoyl derivative (8).
Of note, an attempt to acylate N-Me-D-Phe with decanoic acid failed (7). Although the coupling
of decanoic acid took place efficiently, acidic cleavage with 2% trifluoroacetic acid (TFA) rendered
a compound with a mass corresponding to a loss of N-Dec-N-Me-D-Phe. This kind of fragmentation
has already been described in the literature [18], and occurs as a result of the formation of oxazolonium
ion as an intra-reaction rearrangement (Scheme 1). Since this reaction was reported when acetylation
was attempted, we were confident that the longer chain of the decanoyl vs. the acetyl would minimize
the formation of the side reaction, thereby allowing us to obtain small amounts of the target analog.
Unfortunately, our hypothesis failed and the compound was not obtained. However, our findings
demonstrate that this is a general reaction for the N-acyl N-methyl peptides.
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Scheme 1. Loss of N-Dec-N-Me-D-Phe terminus of analog 7 through oxazolonium formation.
Finally, the modification of the N-terminus to obtain the tetramethyl-N-guanidino-D-Phe (10)
was achieved by treating the free D-Phe N-terminus with HBTU in the presence of DIEA in DMF for
3 h [19].
For all the derivatives except 2, the Alloc protecting group of Arg was removed and all partially
protected peptides were cleaved from the resin using 2% TFA in DCM, without re-protection of the
secondary amines 4 and 5. Cyclization of the analogs was carried out in solution with PyAOP and
OxymaPure in DMF–DCM (1:9) for 2 h. Finally, global deprotection was performed with TFA–TIS–H2O
(95:2.5:2.5) for 2 h. All peptides except 8 were purified by semi-preparative HPLC before testing their
biological activity.
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The most hydrophobic analogs, 5, 6, and 8, presented several difficulties regarding purification.
In this regard, it was not possible to dissolve compound 8 in any solvent system compatible with
reverse-phase chromatography. Nevertheless, by washing the solid obtained several times with 30%
acetonitrile in water, impurities from the cyclization were removed, as were the protecting groups,
and the decanoyl derivative was obtained in good purity (Figure S11). The mixture of compounds
5 and 6 was also a challenge with respect to solubilization. In this case, the addition first of 100 µL of TFA
and then 7 mL of acetonitrile, followed by sonication for 15 min, yielded a clear solution. Then, 3 mL
of water was added slowly and no precipitation of the compounds was observed. This solution was
injected into the semi-preparative HPLC, and the two analogs were separated efficiently.
2.2. Microbiological Evaluation
After the purification and characterization of the new analogs by MALDI-TOF, their antimicrobial
activity was tested against two gram-positive bacteria strains, Staphylococcus aureus and Bacillo subtilis,
as well as two gram-negative strains, namely Escherichia coli and Pseudomonas aeruginosa (Table 1).
The compounds were dissolved at a concentration of 6 mg/mL in 10% DMSO for compounds 1–4
and 60% DMSO for compounds 5, 6, and 8 because of their poor solubility in water. They were then
diluted to reach 512 µg/mL, the highest concentration tested, followed by two-fold serial dilution.
To ensure that DMSO did not interfere in the results, a blank solution of 60% DMSO under the same
dilutions was also assayed.










Teixobactin 1 0.25 0.06 25 >32
1 N-Me-D-Phe-Arg10-teixobactin 2 0.5 64 NI 1
2 D-Phe-Arg10-teixobactin 2 1 32 NI
3 N-Me2-D-Phe-Arg10-teixobactin 16 2 128 NI
4 N-Bz-D-Phe-Arg10-teixobactin 8 2 NI NI
5 N-De-D-Phe-Arg10-teixobactin 1 NI 128 NI NI
6 N-De2-D-Phe-Arg10-teixobactin NI 128 NI NI
8 N-Dec-D-Phe-Arg10-teixobactin 1 NI NI NI NI
9 N-Ac-D-Phe-Arg10-teixobactin 2 NI NI NI NI
10 N-Tmg-D-Phe-Arg10-teixobactin 1 256 64 NI NI
1 De: decanyl, Dec: decanoyl, Tmg: tetramethylguanidino, NI: No inhibition, 2 Described earlier by our group [7].
The Minimum Inhibitory Concentration (MIC) results in Table 1 indicate that an increase in the
lipophilicity of the alkyl substituents leads to a decrease in activity. Thus, the best activity was found
for the parent compound (1), followed by the analog without any substitution (2). The dimethyl
derivative (3) and the benzyl one (4) retained some activity. On the other hand, the two analogs with
one and two decanyl substituents (5, 6) showed total loss of activity. Acylation with decanoic acid (8)
followed the same trend as with the long alkyl chain (5) or just with Ac (9). Although the positive
charge was found to be a requirement for the activity (1, 2, 3, 4), the tetramethylguanidino analog (10)
also showed a significant loss of activity. These data indicate that the modification of the N-terminus
of teixobactin is critical for the activity of the peptide [20].
3. Materials and Methods
3.1. Materials
All reagents and solvents were purchased from commercial sources. Amino acids and
2-chlorotrityl-chloride (CTC) resin were obtained from (Iris Biotech, Marktredwitz, Germany) and N,N-
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Diisopropylethylamine (DIEA) from (Sigma-Aldrich, St. Louis, MO, USA). N,N,N′,N′-tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) and 1-cyano-2-ethoxy-2-oxoethyliden
(aminooxy) dimethylamino-morpholino-carbenium hexafluoro phosphate (COMU) were a gift from
Luxembourg Technologies. Organic solvents were supplied by (Merck, Darmstadt, Germany).
3.2. Instruments
Analytical HPLC was performed on an Agilent 1100 system using a Phenomex LunaC18 (3 µm,
4.6 mm × 50 mm) column (Agilent, Santa Clara, CA, USA), with different gradient methods and using
Buffer A: 0.1% TFA in H2O; buffer B: 0.1% TFA in CH3CN as mobile phase. A flow rate of 1.0 mL/min
and UV detection wavelength of 220 nm were used.
Crude peptides were purified on a Shimadzu LC-8A semi-preparative HPLC using a Phenomenex
LunaC18 (2) column (10 µm, 10 mm × 250 mm), with a flow rate of 7.0 mL/min. The wavelength
detection and mobile phase gradients were the same as those employed for analytical HPLC. Mass
spectrometry was carried out using a Bruker Autoflex III MALDI-TOF mass spectrometer (Bruker,
Billerica, MA, USA) in positive mode and α-Cyano-4-hydroxycinnamic acid (ACH) as the matrix.
3.3. Methods
3.3.1. Chemistry
All Solid Phase Peptide Synthesis (SPPS) steps were carried out manually in a 10-mL
polypropylene syringe fitted with polypropylene frits at room temperature. CTC resin (166 mg,
1.69 mmol/g) was activated using SOCl2–DCM (1:9) (10 mL) overnight. The first amino acid,
Fmoc-L-Ala-OH (31 mg, 0.1 mmol, 1 eq.), was loaded onto the CTC resin in DCM (0.5 mL) in the
presence of DIEA (174 µL, 1 mmol, 10 eq.) as a base and was shaken for 1 h. MeOH (100 µL) was then
added to the reaction mixture, which was left to shake for an additional 30 min to ensure the total
capping of free active sites in the CTC resin.
The rest of the amino acids were incorporated as follows: Fmoc-AA-OH (0.3 mmol, 3 eq.)/HATU
(114 mg, 0.3 mmol, 3 eq.)/DIEA (104 µL, 0.6 mmol, 6 eq.) (3:3:6) in DMF (0.5 mL) for 30 min.
Fmoc removal was accomplished with 20% piperidine in DMF (2 × 2 mL, 5 min). The resin was
washed with DMF (2 × 5 mL), DCM (2 × 5 mL), and DMF (2 × 5 mL) between steps. Esterification
was performed after coupling Fmoc-Ile6-OH using Alloc-L-Ile11-OH (215 mg, 1 mmol, 10 eq.), DIC
(154 µL, 1mmol, 10 eq.) and DMAP (12 mg, 0.1 mmol, 1 eq.) in DCM–DMF (8:2) (0.5 mL) for 2 h.
The Alloc group was removed under nitrogen in a vial shielded from light. The peptide was
treated with a mixture of tetrakistriphenylphosphine palladium (0) (11 mg, 0.01 mmol, 0.1 eq.) and
phenylsilane (124 µL, 1 mmol, 10 eq.) in dry DCM (1 mL) for 15 min. The peptide resin was then
washed with DMF (2 × 5 mL), DCM (2 × 5 mL), and DMF (2 × 5 mL).
Reductive amination was carried out using formaldehyde, benzaldehyde, or decanal (0.6 mmol,
6 eq.) in the presence of NaBH3CN (1.6 mmol, 16 eq.) and AcOH (120 µL) in dry THF (0.5 mL) for
2 h. Coupling with decanoic acid (52 mg, 0.3 mmol, 3 eq.) was performed with DIC (46 µL, 0.3 mmol,
3 eq.) and K-Oxyma (54 mg, 0.3 mmol, 3 eq.) in DMF for 2 h. Guanidine formation was achieved using
HBTU (113 mg, 0.3 mmol, 3 eq.) in DMF (0.5 mL) in the presence of DIEA (104 µL, 0.6 mmol, 6 eq.).
Boc protection was achieved by treating the unprotected peptide with Boc2O (218 mg, 1 mmol, 10 eq.)
and DIEA (174 µL, 1 mmol, 10 eq.) in DMF (2 mL) for 2 h.
The partially protected peptide was cleaved from the CTC resin with TFA–DCM (2:98) (5 mL)
for 10 min, and the solution was filtered off. The treatment was repeated two more times and the
combined filtrates were evaporated to dryness.
Cyclization of all peptides was done in solution by dissolving the corresponding protected peptide
(≈0.1 mmol) in DMF (1 mL), followed by the addition of a mixture of DIEA (0.6 mmol, 6 eq.) and
OxymaPure (0.3 mmol, 3 eq.) in DCM (50 mL). Extra DCM was then added to reach a concentration of
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0.1 mM. The reaction mixture was cooled to 0 ◦C and PyAOP (0.3 mmol, 3 eq.) was added. After 24 h,
DCM was evaporated, and DMF was removed by freeze-drying.
Global deprotection was achieved by treating the fully protected peptide TFA–TIS–H2O (95:2.5:2.5)
(5 mL) for 4 h, followed by washing with cold ether till the peptide precipitated. The supernatant
was then discarded, and the washing was repeated three more times. The solid residue was then
dried. All peptides except analog 8 were purified by semi-preparative HPLC. In each case, fractions
containing the expected peptide were combined, lyophilized, characterized by MALDI-TOF, and
submitted to antimicrobial testing.
3.3.2. Determination of Minimum Inhibitory Concentration (MIC)
The MIC was determined using the broth micro dilution method, as described by the Clinical and
Laboratory Standards Institute (CLSI) guidelines, using two gram-positive and two gram-negative
bacteria strains (Staphylococcus aureus ATCC 29213, Bacillus subtilis ATCC 6051, Escherichia coli
ATCC 25922, Pseudomonas aeruginosa ATCC 27853). First, the bacterial strains were sub-cultured
onto Mueller Hinton agar and incubated at 37 ◦C for 24 h before use in the experiments. Stock
solutions at 6 mg/mL in 10% DMSO were prepared for analogs 1–4 and 60% DMSO for analogs 5, 6,
and 8. Second, two-fold serial dilutions of each drug/compound were made in cation-adjusted Mueller
Hinton broth (CAMHB) in a 96-well microtiter plate. The bacterial inoculum was prepared in distilled
water, matched to a 0.5 McFarland standard, and added to make a final volume of 200 µL in each
microliter well. The plates were incubated for 24 h at 37 ◦C under aerobic conditions. The MIC was
then recorded as the lowest concentration at which no visible growth occurred. Standard drug, media,
and bacterial growth control wells were included in each plate. Meropenem was used as a positive
control and a blank solution of 60% DMSO in water was also tested to ensure that solvent did not
affect the bacterial strains. The assay was performed in triplicate to confirm the results.
4. Conclusions
In conclusion, the N-terminus part of teixobactin accepts minimum changes. Analogs with activity
were achieved only when the Me group from D-Phe was absent or substituted by Bzl, or an extra Me
was present. Interestingly, all analogs that contained a fatty chain either in the form of an acyl or alkyl
showed total loss of activity. The lack of activity of analog 8—where the N-terminal was acylated with
decanoic acid—could be understandable, because in this analog the positive charged was masked as
happened in the acyl analog 9, which was not active either. On the other hand, the lack of activity of
analogs 5 and 6, which contained one and two decanyl chains, respectively, was more unexpected.
In this sense, it should be taken into account that several peptides such as CNY21 enhanced their
activity when lipophilicity was added [12]. Furthermore, the tail of the head to side-chain cyclo peptide
(similar topology than teixobactin) of polymyxin B or colistin ended with a fatty acid. To explain the
lack of activity of analogs 5 and 6, it can be speculated that lipophilicity in cationic peptides such
as CNY21 or polymyxin B/colistin translates to an increase of activity. On the other hand, the same
lipophilicity on already lipophilic peptides such teixobactin could provoke a loss of activity due to the
creation of lipophilic interactions between the fatty chain and the peptide.
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Acknowledgments: This work was funded in part by the following: National Research Foundation (NRF) and
the University of KwaZulu-Natal (South Africa); the International Scientific Partnership Program ISPP at King
Saud University (ISPP# 0061) (Saudi Arabia); and MINECO (CTQ2015-67870-P) and the Generalitat de Catalunya
(2014 SGR 137) (Spain).
Author Contributions: The chemistry was carried out by S.A.H.A.M. with the assistance of S.N. and the
microbiology by E.J.R. Libraries were designed and supervised by A.E.-F., F.A., and B.G.d.l.T. The interpretation
of results and discussion were carried out by the five authors. The first drafts of the manuscript were prepared by
S.A.H.A.M. and the final version included input from all authors.
Conflicts of Interest: The authors declare no conflict of interest.
Molecules 2017, 22, 1632 8 of 9
References
1. Ling, L.L.; Schneider, T.; Peoples, A.J.; Spoering, A.L.; Engels, I.; Conlon, B.P.; Mueller, A.; Schäberle, T.F.;
Hughes, D.E.; Epstein, S. A new antibiotic kills pathogens without detectable resistance. Nature 2015, 517,
455–459. [CrossRef] [PubMed]
2. Jad, Y.E.; Acosta, G.A.; Naicker, T.; Ramtahal, M.; El-Faham, A.; Govender, T.; Kruger, H.G.; Torre, B.G.D.L.;
Albericio, F. Synthesis and biological evaluation of a teixobactin analogue. Org. Lett. 2015, 17, 6182–6185.
[CrossRef] [PubMed]
3. Abdel Monaim, S.A.; Jad, Y.E.; Ramchuran, E.J.; El-Faham, A.; Govender, T.; Kruger, H.G.; de la Torre, B.G.;
Albericio, F. Lysine scanning of Arg10-teixobactin: Deciphering the role of hydrophobic and hydrophilic
residues. ACS Omega 2016, 1, 1262–1265. [CrossRef]
4. Yang, H.; Du Bois, D.; Ziller, J.; Nowick, J. X-ray crystallographic structure of a teixobactin analogue reveals
key interactions of the teixobactin pharmacophore. Chem. Commun. 2017, 53, 2772–2775. [CrossRef]
[PubMed]
5. Parmar, A.; Iyer, A.; Vincent, C.S.; Van Lysebetten, D.; Prior, S.H.; Madder, A.; Taylor, E.J.; Singh, I. Efficient
total syntheses and biological activities of two teixobactin analogues. Chem. Commun. 2016, 52, 6060–6063.
[CrossRef] [PubMed]
6. Abdel Monaim, S.A.; Ramchuran, E.J.; El-Faham, A.; Albericio, F.; de la Torre, B.G. Converting teixobactin
into a cationic antimicrobial peptide (AMP). J. Med. Chem. 2017, 60, 7476–7482. [CrossRef] [PubMed]
7. Abdel Monaim, S.A.; Jad, Y.E.; Ramchuran, E.J.; El-Faham, A.; Acosta, G.A.; Naicker, T.; Govender, T.;
Kruger, H.G.; de la Torre, B.G.; Albericio, F. Re-evaluation of the N-terminal substitution and the D-residues
of teixobactin. RSC Adv. 2016, 6, 73827–73829. [CrossRef]
8. Yang, H.; Chen, K.H.; Nowick, J.S. Elucidation of the teixobactin pharmacophore. ACS Chem. Biol. 2016, 11,
1823–1826. [CrossRef] [PubMed]
9. Setoh, K.; Murakami, M.; Araki, N.; Fujita, T.; Yamamoto, A.; Muranishi, S. Improvement of transdermal
delivery of tetragastrin by lipophilic modification with fatty acids. J. Pharm. Pharmacol. 1995, 47, 808–811.
[CrossRef] [PubMed]
10. Gulaboski, R.; Scholz, F. Lipophilicity of peptide anions: An experimental data set for lipophilicity
calculations. J. Phys. Chem. B 2003, 107, 5650–5657. [CrossRef]
11. Fernández-Llamazares, A.I.; Adan, J.; Mitjans, F.; Spengler, J.; Albericio, F. Tackling lipophilicity of peptide
drugs: Replacement of the backbone N-methyl group of Cilengitide by N-oligoethylene glycol (N-OEG)
chains. Bioconj. Chem. 2013, 25, 11–17. [CrossRef] [PubMed]
12. Orädd, G.; Schmidtchen, A.; Malmsten, M. Effects of peptide hydrophobicity on its incorporation in
phospholipid membranes—An NMR and ellipsometry study. BBA Biomembr. 2011, 1808, 244–252. [CrossRef]
[PubMed]
13. Ramesh, S.; Govender, T.; Kruger, H.G.; Albericio, F.; Beatriz, G. An improved and efficient strategy for the
total synthesis of a colistin-like peptide. Tetrahedron Lett. 2016, 57, 1885–1888. [CrossRef]
14. Okimura, K.; Ohki, K.; Sato, Y.; Ohnishi, K.; Sakura, N. Semi-synthesis of polymyxin B (2–10) and
colistin (2–10) analogs employing the trichloroethoxycarbonyl (Troc) group for side chain protection of
α,γ-diaminobutyric acid residues. Chem. Pharm. Bull. 2007, 55, 1724–1730. [CrossRef] [PubMed]
15. Vaara, M.; Fox, J.; Loidl, G.; Siikanen, O.; Apajalahti, J.; Hansen, F.; Frimodt-Møller, N.; Nagai, J.; Takano, M.;
Vaara, T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
Antimicrob. Agents Chemother. 2008, 52, 3229–3236. [CrossRef] [PubMed]
16. Tsubery, H.; Ofek, I.; Cohen, S.; Fridkin, M. N-terminal modifications of polymyxin B nonapeptide and their
effect on antibacterial activity. Peptides 2001, 22, 1675–1681. [CrossRef]
17. Mingeot-Leclercq, M.-P.; Tulkens, P.M.; Denamur, S.; Vaara, T.; Vaara, M. Novel polymyxin derivatives
are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides 2012, 35, 248–252. [CrossRef]
[PubMed]
18. Teixidó, M.; Albericio, F.; Giralt, E. Solid-phase synthesis and characterization of N-methyl-rich peptides.
J. Pept. Res. 2005, 65, 153–166. [CrossRef] [PubMed]
Molecules 2017, 22, 1632 9 of 9
19. del Fresno, M.; El-Faham, A.; Carpino, L.A.; Royo, M.; Albericio, F. Substituted guanidines: Introducing
diversity in combinatorial chemistry. Org. Lett. 2000, 2, 3539–3542. [CrossRef] [PubMed]
20. Wu, C.; Pan, Z.; Yao, G.; Wang, W.; Fang, L.; Su, W. Synthesis and structure-activity relationship studies of
teixobactin analogues. RSC Adv. 2017, 7, 1923–1926. [CrossRef]
Sample Availability: Samples of the compounds are not available from the authors.
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
